169 related articles for article (PubMed ID: 23968624)
1. Money left on the table: generic drug prices in Canada.
Law MR
Healthc Policy; 2013 Feb; 8(3):17-25. PubMed ID: 23968624
[TBL] [Abstract][Full Text] [Related]
2. The short-term impact of Ontario's generic pricing reforms.
Law MR; Ystma A; Morgan SG
PLoS One; 2011; 6(7):e23030. PubMed ID: 21829581
[TBL] [Abstract][Full Text] [Related]
3. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
4. Private expenditures on brand name prescription drugs after generic entry.
Balaban DY; Dhalla IA; Law MR; Bell CM
Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
[TBL] [Abstract][Full Text] [Related]
5. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
Morgan SG; Li W; Yau B; Persaud N
CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
[TBL] [Abstract][Full Text] [Related]
6. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
7. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
Haas JS; Phillips KA; Gerstenberger EP; Seger AC
Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
[TBL] [Abstract][Full Text] [Related]
8. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
[TBL] [Abstract][Full Text] [Related]
9. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
10. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
11. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
12. Generic competition in Canada.
Steele JW
Pharmacoeconomics; 1994 Nov; 6(5):480-2. PubMed ID: 10155276
[TBL] [Abstract][Full Text] [Related]
13. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
14. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
Wouters OJ; Kanavos PG; McKEE M
Milbank Q; 2017 Sep; 95(3):554-601. PubMed ID: 28895227
[TBL] [Abstract][Full Text] [Related]
15. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
[TBL] [Abstract][Full Text] [Related]
16. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
17. Differences in generic drug prices between the US and Canada.
Gooi M; Bell CM
Appl Health Econ Health Policy; 2008; 6(1):19-26. PubMed ID: 18774867
[TBL] [Abstract][Full Text] [Related]
18. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
19. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.
Kelton CM; Chang LV; Kreling DH
Health Aff (Millwood); 2013 Jul; 32(7):1204-11. PubMed ID: 23836735
[TBL] [Abstract][Full Text] [Related]
20. Lowering generic drug prices: less regulation equals more competition.
Anis AH; Guh DP; Woolcott J
Med Care; 2003 Jan; 41(1):135-41. PubMed ID: 12544550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]